T he STAR*D trial is one of several NIMH-sponsored effectiveness trials of mental health pharmacotherapy and psychotherapy that attempt to examine typical patients in a real-world setting. STAR*D differs from standard RCTs in 6 key ways. The first 3 pertain to study generalizability; that is, broad inclusion criteria with few exclusion criteria, the integration of patient choice, and open-label treatment. The latter 3 pertain to improving treatment strategies; that is, the use of measurement-based care, the use of remission as the primary outcome, and a sequenced treatment approach, including substitution, augmentation, and combination strategies. Rationale for the Effectiveness Study Commonly, RCTs in the unipolar major depression literature recruit patients who are carefully selected to have minimal psychiatric, medical, or substance comorbidities. 1,2 Further, as a result of growing placebo response rates in these trials,